Physician

Christina Cho, MD

According to 2025 Medicare claims, Christina Cho, MD (NPI: 1457650814) practices medical oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 07601-2105.

Cho's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 225 traditional Medicare patients, billed 3,372 HCPCS/CPT codes, and received $143,692 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 370 prescription claims across 55 beneficiaries totaling $436,639 in drug costs, led by Rezurock (Belumosudil Mesylate). 2022 DME data shows 30 claims. Open Payments data shows 4 records totaling $129. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $44,506 to $143,692. Similarly, Part D prescription costs have risen steadily, from $20,825 to $436,639. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	66	472	$44,506
2019	83	376	$36,209
2020	72	440	$40,353
2021	78	481	$47,561
2022	133	1,087	$43,765
2023	250	2,299	$158,897
2024	225	3,372	$143,692

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	24	47	$20,825
2016	15	37	$36,667
2017	24	103	$23,239
2018	33	151	$118,314
2019	56	264	$38,517
2020	53	418	$146,757
2021	47	436	$204,502
2022	69	445	$232,308
2023	62	314	$515,515
2024	55	370	$436,639

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	13	$849
2019	N/R	48	$1,182
2020	N/R	N/R	N/R
2021	22	35	$1,132
2022	N/R	30	$792
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	143	329	$154
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	23	24	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	92	163	$108
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	34	421	$99
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	164	409	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rezurock	Belumosudil Mesylate	11	330	$192,472
Prevymis	Letermovir	11	336	$80,769
Sprycel	Dasatinib	11	330	$49,244
Valacyclovir	Valacyclovir Hcl	39	1,290	$1,247
Levofloxacin	Levofloxacin	24	523	$834

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$129	Kite Pharma, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christina Cho, MD?

Tedicare shows public-source Medicare data for Christina Cho, MD (NPI 1457650814), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christina Cho, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christina Cho, MD?

Christina Cho, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Christina Cho, MD have Open Payments data?

Christina Cho, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.